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The role of ,&blockade therapy for ventricular 
tachycardia induced with isoproterenol: A 
prospective analysis 
lsoproterenol is sometimes required for ventricular tachycardia (VT) induction. However, the role 
of Pblockade for treatment of such VT has not been critically assessed. The use of B-blockade 
was evaluated prospectively in 14 consecutive patients who required isoproterenol 2.4 + 1.3 
(? S. D.) pg/min to induce sustained monomorphic VT (>30 seconds, or requiring termination due 
to hemodynamic collapse) after a negative baseline study. The VT mechanisms were enhanced 
automaticity (group A, six patients), triggered automaticity (group B, three patients), and reentry 
(group C, five patients). Groups A and B had serial intravenous electropharmacologic tests with 
propranolol alone (0.2 mg/kg), verapamil alone (0.15 mg/kg), and propranolol plus verapamil, 
and group C had serial tests with propranolol alone, procainamide or quinidine (class la drug) 
alone, and propranolol plus a class la drug until VT could no longer be induced. All six patients in 
group A responded to propranolol alone. In group B, one patient responded to verapamil alone, 
and two patients responded to propranolol plus verapamll. In group C, three patients responded 
to propranolol alone, one patient responded to a class la drug alone, and one patient responded 
to propranolol plus a class la drug. During a follow-up of 7 to 37 (17.9 -t 10.7) (-tS. D.) months, 
VT has not recurred in any patient. Three patients treated initially with propranolol alone have 
required substitution of amiodarone due to refractory congestive heart failure. In patients 
requiring isoproterenol for VT induction, @blockade alone appears to be effective in preventing 
reinduction of VT caused by enhanced automaticity. A heterogeneous response occurs when the 
VT mechanisms are triggered automaticity or reentry. (AM HEART J 1990;120:1347.) 
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Patients with recurrent, sustained monomorphic 
ventricular tachycardia (VT) sometimes require in- 
travenous administration of ,&agonists such as iso- 
proterenol for initiation of ventricular tachycardia in 
the cardiac electrophysiology laboratory.lv6 Tradi- 
tionally, selection of appropriate antiarrhythmic 
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Table I. Patient characteristics and results 
SCL (msec) VT 
Patient Age (yr) Heart 















RHD 1160 620 890 
CAD 740 480 810 
MVP 790 550 750 
MVP 810 420 750 
RVD 980 530 930 
RVD 925 810 810 
MVP 860 430 820 
CAD 1000 800 930 
RVD 760 490 800 
HTN 580 410 1060 
CAD 830 750 970 
RVD 680 520 670 
None 780 530 920 





















290 PVS (3) 
290 PVS (3) 
260 PVS (2) 
270 PVS (3) 




Effective Long-term F/U 
Mechanism AA (EPT) AA (ml 
EA P Amio 37 
EA P Amio 33 
EA P Nad 25 
EA P Aten 21 
EA P Nad 11 
EA P Aten 7 
R P P 28 
R P Amio 19 
R P Aten 5 
R P,Q Aten,Q 6 
R Proc Proc 8 
TA p,v p,v 2, ‘3 
TA p,v p,v 21 
TA V V 8 
Amio, Amiodarone; Aten, atenolol; AA. antiarrhythmic agent; CAD, coronary artery disease; CL, cycle length: EA, enhanced automaticity; EPT, electro- 
pharmacologic testing; F/U, follow-up; -1, inferior axis; HTN, hypertension; IND, indetereminate; Iso, isoproterenol; Isa/P, isoproterenol + propranolol: 
LBB, left bundle branch configuration; MVP, mitral valve prolapse; Nad, nadolol; OP, overdrive pacing; P. propranolol; Proc, procainamide: PVS, 
programmed ventricular stimulation; Q, quinidine; R, reentry; RBB, right bundle branch configuration; RHD, rheumatic heart disease; RVD, right ventric- 
ular dysplasia: -S, superior axis; SCL, sinus cycle length; Spont, spontaneous; TA. triggered automaticity; V, verapamil; VT, ventricular tachycardia; Num- 
hers in parentheses, number of ventricular extrastimuli. 
therapy for the induced VT has been based upon the 
VT mechanism.5, 6 To date, a critical assessment of 
the role of P-blockade in the treatment of such dys- 
rhythmias has not been undertaken. In this prospec- 
tive study, the role of ,&blockade therapy was eval- 
uated in consecutive patients who required isopro- 
terenol for initiation of VT after a negative baseline 
cardiac electrophysiology study. 
METHODS 
Patient population. Fourteen patients with recurrent, 
sustained monomorphic ventricular tachycardia were eval- 
uated (Table I). There were five males and nine females, 
with an age range of 14 to 78 years. Three patients had cor- 
onary artery disease with a history of myocardial infarc- 
tion, four patients had valvular heart disease, three pa- 
tients had right ventricular dysplasia, one patient had hy- 
pertensive heart disease, and three patients had no clinical 
evidence of structural heart disease. Three patients had VT 
associated with physical exertion, and one patient had VT 
occur during extreme emotional distress. 
Electrophysiology study protocol. Patients were stud- 
ied in the postoperative, fasting state after discontinuation 
of antiarrhythmic therapy for at least 5 half-lives. Midazo- 
lam, 1 to 3 mg, was used intravenously for sedation. Three 
6F quadripolar electrode catheters were inserted percuta- 
neously into the right femoral vein and were positioned 
under fluoroscopic guidance against the high right atrium, 
the right ventricular apex, and across the tricuspid valve to 
record a His bundle potential. Surface electrocardiographic 
leads Vi, I, III, and intracardiac electrograms were re- 
corded on a Siemens-Elema Mingograf recorder (Siemens 
Elema AB, Solna, Sweden) at paper speeds of 25 to 100 
mm/set. A 12-lead electrocardiogram was also recorded 
whenever sustained monomorphic VT was initiated. 
Stimulation was performed with a programmable stim- 
ulator (Bloom Associates, Ltd., Narberth, Pa.), with stim- 
uli having a pulse width of 2 msec and a current twice di- 
astolic threshold. Atria1 overdrive pacing was performed 
initially, beginning at a cycle length of 50 msec less than the 
spontaneous sinus cycle length and decreasing in 50 msec 
intervals to a minimum of 250 to 270 msec. Atria1 pro- 
grammed stimulation with one and two atria1 extrastimuli 
was performed using an atria1 drive cycle length at least 200 
msec greater than the atria1 cycle length that caused Wen- 
kebach periodicity. Ventricular programmed stimulation 
was performed initially at the right ventricular apex. A 
similar protocol was performed at the right ventricular 
outflow tract if VT could not be initiated. Six to eight cycle 
drive trains were used with drive cycle lengths (SiSi) of 600 
and 500 or 400 msec. The inter-train interval was 3 seconds. 
The coupling interval of the first extrastimulus (SiSz) was 
initially 520, 420, or 320 msec, respectively. SiSs was 
decreased in intervals of 10 msec until refractoriness to Sz 
occurred. SiSs was increased by 30 msec, and a second ex- 
trastimulus (S&J was initiated with an interval that was 
300 msec greater than SiSs. SsSs was decreased in 10 msec 
intervals until refractoriness to Ss occurred, and was then 
increased by 20 to 30 msec. SiSs was then decreased again 
in 10 msec intervals until refractoriness of Sz occurred. Af- 
ter stimulation with Ss and Ss was completed with two 
drive cycle lengths, SiSs and SsSs were increased to 30 msec 
more than the effective refractory periods of Ss and Ss, re- 
spectively, and programmed stimulation was continued 
using a third extrastimulus (S&) that was 300 msec 
greater than SsSs. S& was decreased in 10 msec intervals 
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Fig. 1. Sustained ventricular tachycardia (VT) occurred spontaneously in this patient (No. 3) with 
enhanced automaticity during continuous intravenous isoproterenol administration. The coupling interval 
between the last sinus rhythm QRS and the first VT QRS varied from 340 to 420 msec (panels A, 6, and 
C). After intravenous administration of propranolol, this VT did not recur spontaneously when isoprotere- 
no1 was readministered nor could it be induced by programmed ventricular stimulation or ventricular 
overdrive pacing. Shown are a one-second (1 set) time-line, surface electrocardiographic leads Vl, I, and 
III, and intracardiac recordings of atria1 (A), ventricular (V), and His bundle (H) activation from the prox- 
imal (p) and distal (d) high right atrium (HRA), His bundle electrogram (HBE), and atria1 septum (SEP). 
until refractoriness to Sq occurred. S&Id was then increased 
by 20 to 30 msec, and SsS3 was decreased in 10 msec inter- 
vals until refractoriness to Se occurred. After SzSs was in- 
creased again by 30 msec, SiSz was decreased in 10 msec 
intervals until refractoriness to S2 occurred. After comple- 
tion of programmed stimulation with E&S4 using two drive 
cycle lengths, ventricular burst pacing was performed us- 
ing drive cycle lengths of 600 to 260 msec with drive trains 
of 15 cycles. The drive cycle length was decreased by 20 
msec after each train was delivered. The inter-train inter- 
val was 3 seconds. Programmed stimulation at the right 
ventricular outflow tract was performed after completion of 
the protocol at the right ventricular apex. 
Infusion of isoproterenol. After completion of pro- 
grammed stimulation, isoproterenol was infused at rates of 
0.5 to 4.0 rg/min (mean f S. D. = 2.4 f 1.3 rg/min). The 
spontaneous sinus cycle length decreased by 32 + 13 % . If 
VT did not occur spontaneously during isoproterenol ad- 
ministration, programmed stimulation was repeated at 
both right ventricular sites, as previously described. 
Definitions of mechanisms of induced ventricular ta- 
chycardia. The following principles of clinical electrophys- 
iology were utilized to classify the mechanisms of the 
induced VTs.’ 
Enhanced automaticity (group A). VT could not be in- 
duced by programmed stimulation but occurred spontane- 
ously during isoproterenol infusion with varying coupling 
intervals between the last sinus rhythm QRS complex and 
the initial VT QRS complex. The initial VT QRS complex 
had the same morphology as the monomorphic VT. The VT 
could not be converted to sinus rhythm by overdrive pac- 
ing or programmed stimulation, and the VT morphology 
and cycle length did not change after overdrive pacing. 
Advancement of the first post-pacing VT QRS complex did 
not occur after overdrive pacing. The VT resolved only with 
discontinuation of isoproterenol. 
Triggered automaticity (group B). VT could be initiated 
consistently over a specific range of cycle lengths during 
burst ventricular pacing without ventricular extrastimuli. 
The VT cycle length varied with the burst pacing cycle 
length. The first VT QRS complex occurred late in the car- 
diac cycle. This VT could be terminated by burst ventric- 
ular pacing. 
Reentry (group C). VT was initiated with ventricular 
extrastimuli and could be terminated by overdrive pacing. 
Advancement of the first post-pacing VT QRS complex was 
sometimes observed when burst pacing or programmed 
extrastimuli failed to successfully terminate the induced 
VT. 
Electropharmacologic testing 
Groups A and B. During initial electropharmacologic 
testing, propranolol, 0.2 mg/kg, was administered intrave- 
nously and repeat testing was performed using the same 
dose of isoproterenol required to induce VT during the 
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Fig. 2. A through C. In this patient (No. 12) with triggered automaticity, sustained VT could be induced 
only by ventricular overdrive pacing during isoproterenol administration. VT was consistently induced by 
ventricular overdrive pacing at cycle lengths @iSi) of 340 and 360 msec (panels C and D), but not at cycle 
lengths greater than 380 msec (panels A and B) or less than 320 msec (panels E and F). This VT was not 
suppressed with intravenous propranolol alone or verapamil alone, but was suppressed with combined 
therapy with propranolol and verapamil. Ventricular electrograms from the right ventricular apex (RVA) 
are shown. Other abbreviations are the same as in Fig. 1. 
baseline study. If  propranolol alone did not suppress 
reinduction of VT, electropharmacologic testing was re- 
ing upon heart rate and blood pressure response, and 
testing was repeated. 
peated after a minimum of 48 hours using an intrave- 
nous dose of verapamil alone (0.15 mg/kg). I f  verapamil 
alone did not suppress reinduction of VT, propranolol 
was administered in doses of 0.1 to 0.2 mg/kg, depend- 
Group C. Initial electropharmacologic testing of propra- 
nolo1 was performed in a manner similar to that for groups 
A and B. If  propranolol alone did not suppress reinduction 
of VT, electropharmacologic testing was repeated after a 
Volume 120 
Number 6, Part 1 Beta-blockade for isoproterenol-induced VT 1351 
D 




Fig. 2, D through F. For explanation, see legend to Fig. 2, A through C. 
minimum of 48 hours with intravenously administered 
procainamide or quinidine (10 mg/kg load and 0.06 to 0.075 
mg/kg/min). If the class Ia drug did not suppress reinduc- 
tion of VT, propranolol was readministered in a dose of 0.2 
mg/kg and electropharmacologic testing was repeated. 
All patients underwent final testing of orally adminis- 
tered drugs before hospital discharge to confirm that VT 
was not inducible using the previously described protocol 
before and during isoproterenol administration. 
Follow-up. All patients were followed as outpatients 
with office visits every 2 to 3 months for the first 6 months, 
and with office visits or telephone contact every 3 months 
thereafter. 
RESULTS 
The results of electrophysiologic and electrophar- 
macologic testing are summarized in Table I. All 14 
patients required intravenous isoproterenol admin- 
istration to induce sustained VT. Sustained mono- 
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Fig. 3. Initiation of sustained VT during isoproterenol administration in this patient (No. 10) with reen- 
try consistently required three ventricular extrastimuli (SsSsS& during programmed ventricular stimula- 
tion (panel A), and was associated with a fall in blood pressure (BP). Ventricular overdrive pacing (SiSi) 
was uniformly successful in terminating this VT (panel B). Reinduction of this VT could not be suppressed 
by intravenous propranolol alone or quinidine alone. During testing of intravenous propranolol and qui- 
nidine in combination, only nonsustained VT with a maximum duration of seven cycles was induced by 
programmed ventricular stimulation (panel C). Abbreviations are the same as in Figs. 1 and 2. 
morphic VT (duration > 30 seconds, or requiring intravenous isoproterenol administration, the spon- 
termination due to hemodynamic collapse) was in- taneous sinus cycle length decreased to 570 + 130 
duced a minimum of three times in each patient dur- msec 0, < 0.05, paired t test). During continued iso- 
ing isoproterenol administration. The spontaneous proterenol administration after intravenous admin- 
sinus cycle length during the baseline study was istration of propranolol, the spontaneous sinus cycle 
840 a 140 msec (mean k SD.). During continuous length increased to 860 k 100 msec (p > 0.2 versus 
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the sinus cycle length during the baseline study) when compared with those patients who do not 
(paired t test). require isoproterenol for VT induction.6 
Electrophysiologic testing. Six patients had en- 
hanced automaticity (group A) (Fig. l), three 
patients had triggered automaticity (group B) 
(Fig. 2), and five patients had reentry (group C) 
(Fig. 3). 
Electropharmacologic testing. OVerdl, 9 of 14 pa- 
tients (64%) had reinduction of VT suppressed by 
propranolol alone. Three of 14 (21%) patients re- 
quired propranolol combined with other drug ther- 
apy to prevent VT reinduction. 
The presence of both p1 and Pz-adrenoreceptors in 
the human heart has been demonstrated by radioli- 
gand studies.gp lo Both receptor subtypes appear to be 
involved in increasing tissue levels of cyclic adenos- 
ine monophosphate. “1 l2 Isoproterenol is a nonselec- 
tive agonist, whereas propranolol is a nonselective 
antagonist of both 81 and 82 receptors.13r I4 The po- 
tential role that these receptors have in mediating 
activation of each VT mechanism is discussed sepa- 
rately. 
Group A. All six patients with enhanced automa- 
ticity had reinduction of VT suppressed by propra- 
nolo1 alone. 
Group B. None of the three patients with triggered 
automaticity had VT reinduction suppressed by 
propranolol alone. One patient had reinduction of 
VT suppressed by verapamil alone. Two patients had 
reinduction of VT suppressed by propranolol plus 
verapamil. 
Group C. Three patients with reentry had rein- 
duction of VT suppressed by propranolol alone. One 
patient had reinduction of VT suppressed by a class 
Ia drug alone, and one patient had reinduction of VT 
suppressed by propranolol plus a class Ia drug after 
failing to respond to a therapeutic serum concentra- 
tion of the class Ia drug alone. 
Follow-up. Follow-up has ranged from 5 to 37 
(mean -t S.D. = 17.9 + 10.7) months. VT has not 
recurred spontaneously in any patient. Three pa- 
tients treated initially with propranolol alone devel- 
oped refractory congestive heart failure despite pre- 
load and afterload therapy. Because of its indirect fl- 
blocking effects and negligible negative inotropic 
effects when administered orally, amiodarone was 
substituted.8 None of these three patients had in- 
ducible VT after 10 days of oral loading (800 mg twice 
a day), and no patient has had a spontaneous recur- 
rence of VT during long-term oral amiodarone ad- 
ministration (200 mg daily). 
Enhanced automaticity. Spontaneous depolariza- 
tions occur most commonly in cells with slow-re- 
sponse action potentials. 15p l6 In isolated cardiac fiber 
models of spontaneous automaticity, the number of 
functioning slow channels appears to depend upon 
cyclic adenosine monophosphate (CAMP). During 
resting conditions, therefore, there may not be suffi- 
cient slow inward current to cause slow-response ac- 
tion potentials to occur.17 In this setting, it would be 
anticipated that ,&receptor stimulation with isopro- 
terenol might cause automatic VT to occur. Con- 
versely, propranolol would be expected to be effective 
in suppressing such an automatic dysrhythmia. In 
the present study, all patients with VT due to 
enhanced automaticity had VT reinduction sup- 
pressed by P-blockade. Sung et all8 have previously 
reported the failure of verapamil to suppress VT due 
to catecholamine-sensitive automaticity, and have 
postulated that this dysrhythmia may not be caused 
by a slow channel mechanism that is calcium-depen- 
dent in humans. 
DISCUSSION 
Isoproterenol is commonly used to facilitate the 
induction of clinically significant VT when it cannot 
be induced by standard ventricular programmed 
stimulation or burst ventricular pacing.le6 As ob- 
served in this and earlier studies, many of these pa- 
tients’ VTs are not necessarily exercise-induced.5y 6 
The number of patients requiring isoproterenol to 
initiate VT make up a small proportion of the total 
number of patients whose VT is induced in the car- 
diac electrophysiology laboratory. Of the patients 
whose VT requires isoproterenol for initiation, a 
smaller proportion have coronary artery disease 
Triggered automaticity. Triggered automaticity 
caused by delayed afterdepolarizations has been de- 
scribed previously in human tissues.lg In experimen- 
tal models, intracellular calcium overload has been 
observed to occur during sympathetic stimulation. 
Subsequent oscillatory release of calcium by the sar- 
coplasmic reticulum activates a nonselective ion 
channel utilizing a transient sodium current and 
modulated by calcium.20-24 Of interest, one of the 
three patients in the present study had triggered au- 
tomaticity activated by both ventricular extrastimuli 
and ventricular overdrive pacing. In vitro and in vivo 
studies have demonstrated a dependence upon a 
critical range of drive rates or coupling intervals for 
initiation, a cycle length that varies with the cycle 
length of the train of stimuli causing initiation, and 
termination by overdrive pacing, probably due to 
enhancement of sodium extrusion and membrane 
hyperpolarization.25 
Both calcium channel antagonists and B-receptor 
blockers have been demonstrated to reduce calcium 
overload and block the calcium transient. These ac- 
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tions result in either reduction of both the action po- 
tential and the amplitude of delayed action poten- 
tials, or in prevention of delayed afterdepolarization 
altogether.20v 26 In the present study, however, the 
administered intravenous doses of propranolol alone 
and verapamil alone were insufficient for uniformly 
suppressing triggered automaticity activated by iso- 
proterenol. In two of the three patients with triggered 
automaticity, the synergistic effects of P-adrenore- 
ceptor blockade and calcium channel antagonism 
appeared to be necessary to suppress reinduction of 
VT. 
Reentry. Reentry is a dynamic process that requires 
an area of unidirectional impulse block and recircu- 
lation of the impulse to its original point of block.2’ 
When reentry cannot be initiated during resting 
conditions, the discrete responses of individual car- 
diac fibers to isoproterenol stimulation may create 
the milieu for reentry to occur. Under such condi- 
tions, differential shortening of the refractory period 
of individual fibers caused by isoproterenol provides 
a course for impulse propogation along fibers that 
have a shorter refractory period, and blocking in one 
direction in fibers having a longer refractory 
period.28l 2g 
In the presence of isoproterenol, P-blockers in 
concentrations causing ,&blockade alone can reverse 
isoproterenol’s accelerating effects on repolariza- 
tion.30 The inability to reinduce reentrant VT after 
propranolol administration in three of the five pa- 
tients in the present study may have been due to this 
phenomenon. In addition to competitive inhibition of 
catecholamine binding at P-receptor sites, P-blockers 
have been demonstrated to exhibit direct membrane- 
stabilizing action, i.e., “quinidine-like” blockade of 
the inward sodium current. However, this latter ac- 
tion has been observed only at concentrations that 
are up to 100 times greater than the clinical concen- 
trations causing P-blockade.31-34 
Comparison with previous studies. Few studies have 
critically evaluated the role of P-blockade in sup- 
pressing VT that requires isoproterenol for its acti- 
vation. Some studies have utilized intravenous doses 
of propranolol that may have been too small to effect 
adequate blockade of isoproterenol during electro- 
pharmacologic testing, or have not routinely tested 
propranolol in consecutive patients.5, 6 One study3” 
has reported upon the long-term effectiveness of em- 
piric oral B-blocker therapy for patients requiring 
isoproterenol for facilitation of VT induction during 
extrastimulus testing. However, only two of the nine 
patients in that study had sustained VT induced 
prior to antiarrhythmic therapy.35 To our knowledge, 
ate the role of P-blockade in consecutive patients re- 
quiring isoproterenol for induction of sustained VT. 
Conclusions. In patients requiring isoproterenol for 
ventricular induction, p-blockade alone appears to be 
effective in preventing reinduction of VT caused by 
enhanced automaticity. A heterogeneous response 
occurs when the VT mechanisms are triggered auto- 
maticity or reentry. The similarity of the sinus cycle 
lengths measured after treatment with intravenous 
propranolol treatment during continuous isoprotere- 
no1 administration, when compared with the sinus 
cycle lengths measured during the baseline study, 
suggests that adequate blockade of isoproterenol’s 
fl-agonistic effects should have been achieved with 
the dose of propranolol administered in this study. 
The failure of propranolol alone to uniformly sup- 
press all VT activated during isoproterenol adminis- 
tration in this study could have several possible ex- 
planations. These include: (1) differences in the total 
number and the ratio of the subtypes of ,f3-adrenore- 
ceptors that mediated activation of VT mechanisms 
in individual patientslO> 36; (2) differences in the 
affinity of these receptors for propranolol and/or iso- 
proterenol when compared with normal human car- 
diac /3-receptors37; and (3) differences in the intrin- 
sic activity of individual patient’s &receptors in re- 
sponse to isoproterenol and/or propranolol.“s 
Patients who did not respond to intravenously ad- 
ministered propranolol were not retested during 
long-term oral propranolol administration. There- 
fore it is possible that the failure of immediate and 
complete P-blockade to suppress VT reinduction 
may not have predicted the results of long-term 
therapy.3g Further investigation will be necessary to 
substantiate the findings of the present study and to 
better define the role of P-adrenoreceptor activation 
and blockade in human VT mechanisms. 
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